Xcout Intel
iQure Pharma Inc.
iQure Pharma Inc. is a pharmaceutical manufacturing and development company located in Princeton, New Jersey, focused on discovering treatments to restore glutamate balance in central nervous system disorders.
Subscribe to see iQure Pharma Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
iQure Pharma Inc. at a glance
iQure Pharma Inc. is a company headquartered in United States. It has raised at least $8.4M across the 6 funding rounds on record. Its most recent funding round raised $650,000 in May 2026. Xcout tracks 12 named people at iQure Pharma Inc., including Pawel Zolnierczyk (President, CEO).
iQure Pharma Inc. leadership
- Pawel ZolnierczykPresident, CEO
- Henk de WildeChief Operating Officer and R&D Director
- Dr. Art Wamil, MDChief Medical Officer
- Prof. Dr Krzysztof KaminskiChief Scientific Officer
- Pawel ZolnierczykCo-founder & Chief Executive Officer
- Pawel ZolnierczykExecutive Officer
6 more named people on record for iQure Pharma Inc., with roles, board committees and tenure — see the full roster →
iQure Pharma Inc. funding rounds
At least $8.4M raised across the 6 rounds on record. The 5 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $650,000 | — | |
| SEC Form D filing | $2.8M | — | |
| SEC Form D filing | $1.4M | — | |
| SEC Form D filing | $220,000 | — | |
| Series A | $1.8M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent iQure Pharma Inc. news
- FundingPrivate placement (Form D)
Investors
iQure Pharma Inc. competitors
A few of iQure Pharma Inc.'s closest competitors — see the full list of competitors and alternatives →
Cortex Pharmaceuticals, Inc. was a U.S. biopharmaceutical company focused on developing ampakine compounds and other glutamate-receptor modulators for central nervous system disorders. Its intended beneficiaries were patients with conditions such as cognitive impairment, depression, and other neurological or psychiatric disorders, rather than a general consumer market.
Zena Therapeutics Inc. is a privately held, innovative drug discovery and pharmaceutical company headquartered in Princeton, New Jersey.
CereSpir Inc. is a privately held, science-driven pharmaceutical company headquartered in New York with an innovative approach to treating central nervous system disorders.
EIP Pharma, Inc. is a privately held clinical-stage biotechnology company headquartered in Boston, Massachusetts. The company focuses on developing therapeutics for central nervous system (CNS) disorders.
Eleison Pharmaceuticals Inc. is a pharmaceutical company originally organized as a Delaware corporation in 2009 and headquartered in Princeton, New Jersey.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for central nervous system disorders. Its pipeline focuses on treating conditions such as suicidal depression, suicidal bipolar depression, and post-traumatic stress disorder. The company utilizes a proprietary NMDA platform for its therapeutic developments.
Get iQure Pharma Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on iQure Pharma Inc. in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 6 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access